Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: A nationwide population-based study in Taiwan

Rheumatology (United Kingdom)

Volumn 52, Issue 1, 2013, Pages 166-172

  Chang, Yu Sheng ^a,b   Liu, Chia Jen ^b   Wu, Tsai Hung ^b,c   Chaou, Chung Hsien ^d   Lin, Kuan Chia ^e   Ou, Shou Ming ^b,c   Chen, Tzeng Ji ^b,c   Chen, Wei Sheng ^b,c   Chou, Chung Tei ^b,c   Tsai, Chang Youh ^b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

End stage renal disease; Haemodialysis; Lupus nephritis; Peritoneal dialysis; Systemic lupus erythematosus

Indexed keywords

PREDNISOLONE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG FATALITY; DRUG MEGADOSE; FEMALE; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTHESIS INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEPTICEMIA; SEX DIFFERENCE; SURVIVAL; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN;

ADULT; AGED; DATABASES, FACTUAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84871142308     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes325     Document Type: Article

References (18)

1. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010;19: 557-74.
2. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3: 423-53.
3. Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med 1990;89: 169-74.
4. Weng CH, Hsu CW, Yu CC et al. Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes. Kidney Blood Press Res 2009;32: 451-6.
5. Goo YS, Park HC, Choi HY et al. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J 2004;45: 199-206.
6. Siu YP, Leung KT, Tong MKH, Kwan TH, Mok CC. Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2005;20: 2797-802.
7. Huang J, Hung K, Yen C, Wu K, Tsai T. Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious complications. Perit Dial Int 2001;21: 143-7.
8. Mojcik CF, Kuppel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996;101: 100-7.
9. Shafi ST, Gupta M. Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. J Vasc Access 2007;8: 103-8.
10. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001;56: 428-34.
11. Prieto LN, Suki WN. Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis 1994;23: 587-90.
12. Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010;19: 119-29.
13. Lai CC, Tan CK, Huang YT et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin Infect Dis 2008;47: e57-63.
14. Treatment modalities for ESRD patients. United States Renal Data System. Am J Kidney Dis 1998;32: S50-9.
15. Chen HA, Wang JJ, Chou CT et al. Predictors of longterm mortality in patients with and without systemic lupus erythematosus on maintenance dialysis: a comparative study. J Rheumatol 2011;38: 2390-4.
16. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. Q J Med 1990;74: 63-74.
17. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheum 2008;4: 525-33.
18. Krane NK, Burjak K, Archie M, O'Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 1999;33: 872-9.